759P Adding dosing of plasmid encoding p62/SQSTM1 to gemcitabine chemotherapy may provide clinical benefits to patients with platinum-resistant ovarian cancer

Autor:	A. Khorau, E. Zhavrid, O. Sergeeva, S. Kozlovskaya, S. Polyakov, A. Shneider, K. Zharkova, V. Gabai, Y. Baranau, S. Krasny
Rok vydání:	2021
Předmět:	Chemotherapy business.industry medicine.medical_treatment Hematology medicine.disease Gemcitabine Plasmid Oncology Cancer research Medicine Dosing business Ovarian cancer Platinum resistant medicine.drug
Zdroj:	Annals of Oncology. 32:S747-S748
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.1201
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::955e45b522f48dfbc0031b3ef6c20c82 https://doi.org/10.1016/j.annonc.2021.08.1201 Zobrazit plný text záznamu